Medical Equipment Stock Performance Review -- Amedica, Steris, Smith & Nephew, and Globus Medical

Monday, October 16, 2017 Medical Gadgets
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, October 16, 2017 /PRNewswire/ --

If you want a Stock Review on AMDA, STE, SNN, or GMED then come over to and sign up for your free customized report. has issued research reports on Amedica Corp. (NASDAQ: AMDA), Steris PLC (NYSE: STE), Smith & Nephew PLC (NYSE: SNN), and Globus Medical
Inc. (NYSE: GMED). Companies in the Medical Appliances and Equipment space are structured as corporations most of the time and tend to offer below-average dividend yields when compared to the wider market. These free stocks reports are currently available on Simply sign up for your complimentary member access at:


Salt Lake City, Utah headquartered Amedica Corp.'s shares rose 2.71%, finishing last Friday's session at $0.30. A total volume of 130,584 shares was traded. The stock is trading below its 50-day moving average by 6.09%. Additionally, shares of Amedica, which develops, manufactures, and sells a range of medical devices based on its silicon nitride ceramic technology platform in the US, Europe, and South America, have a Relative Strength Index (RSI) of 47.54.

On September 22nd, 2017, Amedica announced its preliminary earnings report for Q1 and Q2 ended March 31st, 2017, and June 30th, 2017, respectively. For Q1 2017, preliminary unaudited revenue was $2.6 million and preliminary unaudited GAAP net loss was $0.07 per share. For Q2 2017, preliminary unaudited revenue was $3.2 million and preliminary unaudited GAAP net loss was $0.05 per share.

On September 25th, 2017, research firm Maxim Group downgraded the Company's stock rating from 'Buy' to 'Hold'. Your complete research report on AMDA can be retrieved for free at:


On Friday, shares in Leicester, the UK headquartered Steris PLC ended the session 1.23% lower at $89.49. The stock recorded a trading volume of 450,553 shares, which was above its three months average volume of 399,220 shares. The Company's shares have gained 3.10% in the last month, 8.54% in the previous three months, and 32.79% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 3.06% and 15.98%, respectively. Moreover, shares of Steris, which develops, manufactures, and markets infection prevention, contamination control, microbial reduction, and surgical and gastrointestinal support products and services for healthcare, pharmaceutical, scientific, research, industrial, and governmental customers worldwide, have an RSI of 57.24.  A free report on STE is just a click away at:

Smith & Nephew 

London, the UK headquartered Smith & Nephew PLC's stock climbed 0.63%, to close the day at $38.50. A total volume of 590,607 shares was traded, which was above their three months average volume of 517,460 shares. The Company's shares have advanced 4.56% in the last one month, 9.87% over the previous three months, and 27.99% since the start of this year. The stock is trading 6.54% and 15.06% above its 50-day and 200-day moving averages, respectively. Additionally, shares of the Company, which designs, develops, and sells medical devices worldwide, have an RSI of 70.29.

On October 11th, 2017, research firm Canaccord Genuity initiated a 'Buy' rating on the Company's stock, with a target price of $42 per share. Sign up for your complimentary research report on SNN at:

Globus Medical 

Shares in Audubon, Pennsylvania headquartered Globus Medical Inc. recorded a trading volume of 881,338 shares, which was above their three months average volume of 669,350 shares. The stock ended at $28.86, slightly down 0.48% from the last trading session. The Company's shares have gained 16.32% on an YTD basis. The stock is trading below its 200-day moving average by 2.84%. Furthermore, shares of Globus Medical, which focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders, have an RSI of 40.15.

On October 10th, 2017, Globus Medical announced the first spine surgeries using ExcelsiusGPS™, a revolutionary robotic guidance and navigation system. Surgeries using ExcelsiusGPS™ were performed a week before at The Johns Hopkins Hospital in Baltimore, Maryland and St. Mark's Hospital in Salt Lake City, Utah. The surgical team at Johns Hopkins was led by neurosurgeons Dr. Nick Theodore and Dr. Ali Bydon, while orthopedic spine surgeon Dr. Kade Huntsman performed the surgeries at St. Marks. Register for free on and download the latest research report on GMED at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store